Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023DZMEC-290-02 | Other Identifier | Ethics Committee of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| treatment group（Jiajian Guishen Formulation） | Experimental | Jiajian Guishen Formulation is a traditional Chinese medicine, it will be used in POI patients for three menstrual cycles; their blood samples are collected before and after treatment. |
|
| no-treatment control group | No Intervention | healthy people |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Jiajian Guishen Formulation | Drug | Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment. |
| Measure | Description | Time Frame |
|---|---|---|
| follicle stimulating hormone,FSH | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| Measure | Description | Time Frame |
|---|---|---|
| anti mullerian hormone, AMH | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| Evaluation of the efficacy of Traditional Chinese Medicine symptoms |
Not provided
Inclusion Criteria:
POI Inclusion Criteria:
The above five items must be met to be included in the POI patient group in this study.
Healthy subjects inclusion criteria:
Exclusion Criteria:
POI exclusion criteria:
Those who met any of the above 5 criteria were excluded from this study. Healthy subjects were excluded as (1), (3), (4), (5).
biological
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yun Shi | Dongzhimen Hospital of Beijing University of Chinese Medicine | Study Director |
| Ke Xu, Master | Dongzhimen Hospital of Beijing University of Chinese Medicine | Principal Investigator |
| Jing yi Shao, Master | Dongzhimen Hospital of Beijing University of Chinese Medicine | Study Chair |
| Xi yu Li, Bachelor | Dongzhimen Hospital of Beijing University of Chinese Medicine | Study Chair |
| Qin yang Liu, Bachelor | Dongzhimen Hospital of Beijing University of Chinese Medicine | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dongzhimen Hospital, Beijing University of Chinese Medicine | Beijing | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
A sacle score to evalyate the symptoms, results of scores ranges from 0 to 108, higher scores mean more severe condition of POI.The main symptoms include menstrual cycle, menstrual flow reduction. Scoring criteria: ① normal menstrual cycle 0 points, 1-2 weeks ahead or behind the wrong 4 points, 2-3 weeks 8 points, more than 3 weeks 12 points; ② menstrual flow than the previous menstrual flow no change 0 points, menstrual flow reduction ≤ ⅓ 4 points, ⅓ < menstrual flow reduction ≤ ½ 8 points, menstrual flow reduction > ½ 12 points. Secondary symptoms included lumbar and knee pain, dizziness and tinnitus, loss of libido, increased urination, hot flashes and night sweats, and lower back and lower limb pain et. According to the degree of aggravation of symptoms, the total score was assigned as 0,2,4,8.
| before and1 month after the treatment |
| Improved Kupperman Scale Scoring | A sacle score to evalyate the symptoms, results of scores ranges from 0 to 39, higher scores mean more severe condition of POI.Referring to the domestic modified Kupperman Symptom Scoring Criteria in Chinese Obstetrics and Gynecology, edited by Cao Zeyi, to observe and rate perimenopausal symptoms before and after treatment and to quantify the degree of decline in ovarian function.Entries include hot flashes and sweating, sensory abnormalities, insomnia, anxiety and depression, dizziness, fatigue, muscle and joint pain, headache, palpitations, ankylosis of the skin, sexual discomfort, and urinary irritation, with different coefficients for each entry, and according to the aggravating degree of the symptom, they are divided into 0, 1, 2, and 3 points, and the coefficients corresponding to the scoring of the degree of each item are multiplied by a fixed score of the symptom to add up to the total score. | before and 1 month after the treatment |
| estradiol, E2 | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| luteinizing hormone, LH | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| testosterone, T | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| malondialdehyde | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| superoxide dismutase | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| reduced glutathione, GSH | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| ceruloplasmin | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| copper | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| metabolite level | Blood samples are collected before and after treatment. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| Differential metabolites and their related indexes of mechanism pathways | The results of differential metabolites and their related indexes of mechanism pathways cann't be predicted until the metabolomics test finish, because the test include hundreds of metabolites. Metabolomics results will be tested by using liquid chromatography coupled with mass spectrometry (LC-MS) to identify potential markers.All multivariate analyses and modeling on the normalized data were carried out using software SIMCA-P. Supervised analysis (orthogonal partial least squares discriminate analysis, OPLS-DA) was applied to distinguish metabolic difference between normal group and POI group. SPSS 22.0 (SPSS Inc) software was used for receiver operating characteristic (ROC) curve analyses and binary logistic regression analyses. Then their related indexes of mechanism pathways will be tested in blood samples. | Differential metabolites will be tested on the 2~4th day of menstruation (amenorrhea patients before and after taking medication), related indexes of mechanism pathways will be tested after the analyses of differential metabolities |
| Number of participants with abnormal laboratory test of blood routine examination results | Blood samples are collected before and after treatment. white blood cell count (WBC), red blood cell (RBC) and platelet count/blood platelet count (PLT) are included. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| Number of participants with abnormal Liver and kidney function (by laboratory test results) | Blood samples are collected before and after treatment. creatinine(CREA), uric acid (UA), alanine amiotransferase(AST), aspartate aminotransferase (AST) and γ-glutamyl transpeptadase (GGT) are included. | On the 2~4th day of menstruation (amenorrhea patients before and after taking medication) |
| ID | Term |
|---|---|
| D016649 | Primary Ovarian Insufficiency |
| ID | Term |
|---|---|
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
Not provided
Not provided